Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems
Top Cited Papers
Open Access
- 1 February 2000
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 53 (2) , 125-130
- https://doi.org/10.1136/jcp.53.2.125
Abstract
Aims—To investigate interlaboratory variance in the immunohistochemical (IHC) detection of oestrogen receptors so as to determine the rate of false negatives, which could adversely influence the decision to give adjuvant tamoxifen treatment. Methods—To ensure that similar results are obtained by different institutions, 200 laboratories from 26 countries have joined the UK national external quality assessment scheme for immunocytochemistry (NEQAS-ICC). Histological sections from breast cancers having low, medium, and high levels of oestrogen receptor expression were sent to each of the laboratories for immunohistochemical staining. The results obtained were evaluated for the sensitivity of detection, first by estimating threshold values of 1% and 10% of stained tumour cells, and second by the Quick score method, by a panel of four assessors judging individual sections independently on a single blind basis. The results were also evaluated using participants' own threshold values. Results—Over 80% of laboratories were able to demonstrate oestrogen receptor positivity on the medium and high expressing tumours, but only 37% of laboratories scored adequately on the low expressing tumour. Approximately one third of laboratories failed to register any positive staining in this tumour, while one third showed only minimal positivity. Conclusions—There is considerable interlaboratory variability, especially in relation to the detection of breast cancers with low oestrogen receptor positivity, with a false negative rate of between 30% and 60%. This variability appears to be caused by minor differences in methodology that may be rectified by fine adjustment of overall technique.Keywords
This publication has 14 references indexed in Scilit:
- Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assuranceEuropean Journal Of Cancer, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Prognostic and predictive factors in breast cancer by immunohistochemical analysis.1998
- Oestrogen receptors and breast cancerBMJ, 1997
- A Phoenix Arisen-Estrogen Receptor ImmunohistochemistryJournal of Histotechnology, 1997
- Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Spγ in frozen sections or cytosol-based ligand-binding assaysCancer, 1996
- Oestrogen Receptor Analysis of Paraffin Sections and Cytosol Samples of Primary Breast Cancer in Relation to Outcome After Adjuvant Tamoxifen TreatmentActa Oncologica, 1996
- Comparison of two antibodies for evaluation of estrogen receptors in paraffin-embedded tumors.1993
- Production of monoclonal antibodies to human estrogen‐receptor protein (ER) using recombinant ER (RER)International Journal of Cancer, 1993
- IMMUNOCYTOCHEMICAL ANALYSIS OF ESTROGEN-RECEPTORS AS A PREDICTOR OF PROGNOSIS IN BREAST-CANCER PATIENTS - COMPARISON WITH QUANTITATIVE BIOCHEMICAL METHODS1989